115 related articles for article (PubMed ID: 14763140)
1. [Pharmacological consequences of the targeting of epidermal growth factor receptor].
Milano G; Magné N
Bull Cancer; 2003 Nov; 90 Spec No():S197-201. PubMed ID: 14763140
[TBL] [Abstract][Full Text] [Related]
2. [Targeting epidermal growth factor receptor in cancer of the breast].
Diéras V; Pierga JY; Vincent-Salomon A; Beuzeboc P; Pouillart P; de Cremoux P
Bull Cancer; 2003 Nov; 90 Spec No():S257-62. PubMed ID: 14763149
[TBL] [Abstract][Full Text] [Related]
3. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
4. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
5. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors.
Ritter CA; Arteaga CL
Semin Oncol; 2003 Feb; 30(1 Suppl 1):3-11. PubMed ID: 12644979
[TBL] [Abstract][Full Text] [Related]
6. Novel toll-like receptor 9 agonist induces epidermal growth factor receptor (EGFR) inhibition and synergistic antitumor activity with EGFR inhibitors.
Damiano V; Caputo R; Bianco R; D'Armiento FP; Leonardi A; De Placido S; Bianco AR; Agrawal S; Ciardiello F; Tortora G
Clin Cancer Res; 2006 Jan; 12(2):577-83. PubMed ID: 16428503
[TBL] [Abstract][Full Text] [Related]
7. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.
Vokes EE; Chu E
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):15-25. PubMed ID: 16736979
[TBL] [Abstract][Full Text] [Related]
9. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
10. Epidermal Growth Factor Receptor (EGFR) Inhibitors and Cancer Therapeutics. Proceedings of the Radiation Therapy Oncology Group Symposium. Philadelphia, Pennsylvania, USA. June 14, 2002.
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):898-1007. PubMed ID: 14967448
[No Abstract] [Full Text] [Related]
11. Combining EGFR inhibitors with radiation or chemotherapy: will preclinical studies predict clinical results?
Harari PM; Huang SM
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):976-83. PubMed ID: 14967459
[TBL] [Abstract][Full Text] [Related]
12. Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.
Oliveras-Ferraros C; Vazquez-Martin A; López-Bonet E; Martín-Castillo B; Del Barco S; Brunet J; Menendez JA
Int J Oncol; 2008 Dec; 33(6):1165-76. PubMed ID: 19020749
[TBL] [Abstract][Full Text] [Related]
13. Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.
Diasio RB; Fourie J
Drugs; 2006; 66(11):1441-63. PubMed ID: 16906777
[TBL] [Abstract][Full Text] [Related]
14. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor-targeted therapy potentiates lovastatin-induced apoptosis in head and neck squamous cell carcinoma cells.
Mantha AJ; McFee KE; Niknejad N; Goss G; Lorimer IA; Dimitroulakos J
J Cancer Res Clin Oncol; 2003 Nov; 129(11):631-41. PubMed ID: 12942316
[TBL] [Abstract][Full Text] [Related]
16. [Molecular target-based cancer therapy: epidermal growth factor receptor inhibitors].
Tamura T
Nihon Geka Gakkai Zasshi; 2002 Feb; 103(2):233-6. PubMed ID: 11904986
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
18. EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs.
Arteaga CL
J Clin Oncol; 2003 Dec; 21(23 Suppl):289s-291s. PubMed ID: 14645415
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor-targeted therapy in colorectal cancer.
O'dwyer PJ; Benson AB
Semin Oncol; 2002 Oct; 29(5 Suppl 14):10-7. PubMed ID: 12422309
[TBL] [Abstract][Full Text] [Related]
20. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
